[Prognostic significance of Ph-positive acute lymphoblastic leukemia].
Lists
Only you see this
Abstract
allo-HSCT was an optimal choice for Ph⁺ALL patients. Imatinib-based therapy could increase CR rate, maintain CR duration and decrease relapse, resulting in more chance of HSCT. Imatinib improved the outcomes of Ph⁺ALL patients who were not eligible for HSCT.
BibTeX
@inproceedings{zhou2014prognostic,
author = {Li Zhou and Jiong Hu and Juan Chen and Shenghong Du and Aihua Wang and Jianhua You and Wen Wu and Zhixiang Shen and Junmin Li},
title = {{[Prognostic significance of Ph-positive acute lymphoblastic leukemia].}},
booktitle = {PubMed},
year = {2014},
doi = {10.3760/cma.j.issn.0253-2727.2014.02.011},
}Loading related content...